Ventyx Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ventyx Biosciences, Inc.
Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
Does Zydus’ Promising CAPS Candidate Have An Edge Over Novartis’ Ilaris?
Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?
Five Pivotal Trial Read-Outs To Look Out For In Early 2022
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
Finance Watch: Four New IPOs Hold Steady In First Days Of Trading
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Oppilan Pharma Inc., Zomagen Biosciences Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.